Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Cabometyx is a prescription kinase inhibitor containing cabozantinib. It is approved for advanced renal cell carcinoma, selected hepatocellular carcinoma, differentiated thyroid cancer, and selected pancreatic or extra-pancreatic neuroendocrine tumors. Some indications include patients age 12 and older. Cabometyx comes as 20 mg, 40 mg, and 60 mg tablets taken by mouth.
read more about cabometyx ...Cabozantinib inhibits several receptor tyrosine kinases involved in tumor growth, blood vessel formation, metastasis, and cancer cell survival. Targets include MET, VEGFR-1, VEGFR-2, VEGFR-3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3, and TIE-2. Blocking these pathways reduces signaling linked to tumor progression.
Cabometyx treats advanced renal cell carcinoma and is also paired with nivolumab for first-line advanced renal cell carcinoma. Other indications include hepatocellular carcinoma after prior sorafenib, selected differentiated thyroid cancer after VEGFR-targeted therapy, and previously treated unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Adults commonly take 60 mg once daily when Cabometyx is used alone for renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, or neuroendocrine tumors. Combination treatment with nivolumab uses 40 mg once daily. Tablets are taken on an empty stomach at least one hour before or two hours after eating and are swallowed whole.
Serious risks include hemorrhage, gastrointestinal perforation or fistula, blood clots, high blood pressure, heart failure, severe diarrhea, hand-foot syndrome, liver injury, adrenal insufficiency, proteinuria, jaw osteonecrosis, impaired wound healing, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, low calcium, and fetal harm. Blood pressure, liver tests, urine protein, thyroid function, and calcium require monitoring.
Cabometyx has indications for selected kidney, liver, thyroid, and neuroendocrine cancers under specific treatment criteria.
No. Cabometyx is taken at least one hour before or at least two hours after eating.
No. Current prescribing information directs patients to swallow Cabometyx tablets whole.
No. Cabometyx tablets should not be substituted directly with cabozantinib capsules.
CABOMETYX (cabozantinib) Prescribing Information. https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf. Date Accessed September 21, 2026.
Cabozantinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a616037.html. Date Accessed September 21, 2026.
Cabozantinib-S-Malate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/cabozantinib-s-malate. Date Accessed September 21, 2026.
DailyMed - CABOMETYX (cabozantinib) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3850cce2-6137-42e5-a792-d318c4a4b3b5. Date Accessed September 21, 2026.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With pNET and epNET. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet. Date Accessed September 21, 2026.